BHVN – biohaven pharmaceutical holding company ltd. common shares (US:NASDAQ)

News

Biohaven (NYSE:BHVN) was downgraded by analysts at HC Wainwright from a "buy" rating to a "neutral" rating.
Biohaven (BHVN): Assessing Valuation After Recent Share Price Boost [Yahoo! Finance]
Biohaven (NYSE:BHVN) was downgraded by analysts at UBS Group AG from a "buy" rating to a "neutral" rating.
Biohaven (NYSE:BHVN) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Biohaven (NYSE:BHVN) had its price target lowered by analysts at JPMorgan Chase & Co. from $47.00 to $15.00. They now have an "overweight" rating on the stock.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com